Meeting
2018 ASCO Annual Meeting
A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers.
Presenter
Bob T. Li, MD, MPH
Memorial Sloan Kettering Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Immunoconjugates
Clinical Trial Registration Number
NCT02675829
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2502)
DOI
10.1200/JCO.2018.36.15_suppl.2502
Abstract #
2502
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2019 ASCO Annual Meeting
Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial.
Speaker: Bob T. Li, MD, MPH
Videos & Slides
2018 ASCO Annual Meeting
Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial.
Speaker: Komal L. Jhaveri, MD, FACP
Videos & Slides
2017 ASCO Annual Meeting
Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers: Results from a phase II basket trial.
Speaker: Bob T. Li, MD, MPH, FRACP
Videos & Slides
2023 ASCO Annual Meeting
Tissue-agnostic efficacy of trastuzumab deruxtecan (T-DXd) in advanced solid tumors with HER2 amplification identified by plasma cell-free DNA (cfDNA) testing: Results from a phase 2 basket trial (HERALD/EPOC1806).
Speaker: Hiroya Taniguchi, MD, PhD